1. Ontak Approved to Treat T-Cell Lymphoma - US News and World Report
FRIDAY, Oct. 17 (HealthDay News) -- The Eisai Corp. drug Ontak (denileukin diftitox) has been approved to treat cutaneous T-cell lymphoma (CTCL) whose cells contain a certain receptor known as IL2. A receptor is a molecule found on the surface of ce...

2. Incidence of Mantle Cell Lymphoma on Rise - US News and World Report
FRIDAY, July 18 (HealthDay News) -- The prevalence of mantle cell lymphoma, an aggressive form of non-Hodgkin lymphoma, is increasing, and most patients are diagnosed with advanced stages of the disease, notes a study by researchers at the Universit...

3. Non-Hodgkin's lymphoma  (Trust Mark: Doctor-Reviewed)
Non-Hodgkin's lymphoma is cancer of the lymphoid tissue, which includes the lymph nodes, spleen, and other organs of the immune system.• Reviewer: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

4. Burkitt lymphoma  (Trust Mark: Doctor-Reviewed)
Burkitt lymphoma is a very fast growing form of non-Hodgkin's lymphoma.• Reviewer: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.